Protagonist Therapeutics (PTGX) Initiated with a Buy at Leerink Partners

Protagonist Therapeutics (PTGX) received a Buy rating and a $41.00 price target from Leerink Partners analyst Joseph Schwartz on March 22. The company’s shares closed last Thursday at $27.53.

According to, Schwartz is a 5-star analyst with an average return of 16.5% and a 47.7% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and KalVista Pharmaceuticals.

Currently, the analyst consensus on Protagonist Therapeutics is a Strong Buy with an average price target of $37.33, a 38.3% upside from current levels. In a report issued on March 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $36.00 price target.

See today’s analyst top recommended stocks >>

Protagonist Therapeutics’ market cap is currently $1.36B and has a P/E ratio of -15.60. The company has a Price to Book ratio of 4.87.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm’s initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn’s disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts